Lars Erichsen

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Juan P. Frías, Srikanth Deenadayalan, Lars Erichsen et al. · The Lancet · 2023 · 264 citations

Diabetes Management, Diabetes, Pharmacology +6

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco et al. · The Lancet · 2021 · 211 citations

Obesity, Metabolic Syndrome, Dose-finding Phase 2 +10

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

Tim Heise, Thomas R. Pieber, Thomas Danne et al. · Clinical Pharmacokinetics · 2017 · 178 citations · Full text

Gender difference in antidiuretic response to desmopressin

Kristian Vinter Juul, Bjarke M. Klein, Rikard Sandström et al. · American Journal of Physiology-Renal Physiology · 2011 · 121 citations

Pharmacotherapy, Female Reproductive Function, Reproductive Endocrinology +19

Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus

Maryam Fath, Thomas Danne, Torben Biester et al. · Pediatric Diabetes · 2017 · 69 citations · Full text